Carlo Bertozzi

Carlo Bertozzi is a professional in the pharmaceutical and biotechnology sectors, currently serving as the CEO and Co-Founder of InCephalo, a company focused on drug development. Prior to this role, he was the CEO of G7 Therapeutics, a Swiss biotech firm specializing in the development of novel medicines targeting G protein-coupled receptors (GPCRs) until its rebranding to Heptares Zurich in late 2016.2

Bertozzi is also recognized for his involvement with Veranova, where he is a member of the advisory board alongside other industry leaders. Veranova specializes in the development and manufacturing of complex active pharmaceutical ingredients (APIs) for the biotech and pharmaceutical sectors.14 His expertise and leadership contribute significantly to advancing therapeutic innovations in these fields.

On LinkedIn, Bertozzi's profile indicates he has a strong professional network and background in business management, having studied at IMD Business School in Zürich.3